Literature DB >> 11948178

Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family.

Lin Gao1, Maria A Cueto, Fred Asselbergs, Peter Atadja.   

Abstract

We have cloned and characterized a human cDNA that belongs to the histone deacetylase family, which we designate as HDAC11. The predicted HDAC11 amino acid sequence reveals an open reading frame of 347 residues with a corresponding molecular mass of 39 kDa. Sequence analyses of the putative HDAC11 protein indicate that it contains conserved residues in the catalytic core regions shared by both class I and II mammalian HDAC enzymes. Putative orthologues of HDAC11 exist in primate, mouse, Drosophila, and plant. Epitope-tagged HDAC11 protein expressed in mammalian cells displays histone deacetylase activity in vitro. Furthermore, HDAC11's enzymatic activity is inhibited by trapoxin, a known histone deacetylase inhibitor. Multiple tissue Northern blot and real-time PCR experiments show that the high expression level of HDAC11 transcripts is limited to kidney, heart, brain, skeletal muscle, and testis. Epitope-tagged HDAC11 protein localizes predominantly to the cell nucleus. Co-immunoprecipitation experiments indicate that HDAC11 may be present in protein complexes that also contain HDAC6. These results indicate that HDAC11 is a novel and unique member of the histone deacetylase family and it may have distinct physiological roles from those of the known HDACs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11948178     DOI: 10.1074/jbc.M111871200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  201 in total

1.  Analysis of histone acetyltransferase and histone deacetylase families of Arabidopsis thaliana suggests functional diversification of chromatin modification among multicellular eukaryotes.

Authors:  Ritu Pandey; Andreas Müller; Carolyn A Napoli; David A Selinger; Craig S Pikaard; Eric J Richards; Judith Bender; David W Mount; Richard A Jorgensen
Journal:  Nucleic Acids Res       Date:  2002-12-01       Impact factor: 16.971

Review 2.  Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries.

Authors:  Na'ama A Shein; Esther Shohami
Journal:  Mol Med       Date:  2011-01-25       Impact factor: 6.354

Review 3.  Histone deacetylases in kidney development: implications for disease and therapy.

Authors:  Shaowei Chen; Samir S El-Dahr
Journal:  Pediatr Nephrol       Date:  2012-06-22       Impact factor: 3.714

4.  Modulation of histone deacetylase 6 (HDAC6) nuclear import and tubulin deacetylase activity through acetylation.

Authors:  Yuanjing Liu; Lirong Peng; Edward Seto; Suming Huang; Yi Qiu
Journal:  J Biol Chem       Date:  2012-07-09       Impact factor: 5.157

Review 5.  Therapeutic Approaches to Histone Reprogramming in Retinal Degeneration.

Authors:  Andre K Berner; Mark E Kleinman
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

Review 6.  Epigenomics and breast cancer.

Authors:  Pang-Kuo Lo; Saraswati Sukumar
Journal:  Pharmacogenomics       Date:  2008-12       Impact factor: 2.533

Review 7.  Molecular brake pad hypothesis: pulling off the brakes for emotional memory.

Authors:  Annie Vogel-Ciernia; Marcelo A Wood
Journal:  Rev Neurosci       Date:  2012       Impact factor: 4.353

8.  Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases.

Authors:  C James Chou; David Herman; Joel M Gottesfeld
Journal:  J Biol Chem       Date:  2008-10-24       Impact factor: 5.157

9.  Role for histone deacetylase 1 in human tumor cell proliferation.

Authors:  Silvia Senese; Katrin Zaragoza; Simone Minardi; Ivan Muradore; Simona Ronzoni; Alfonso Passafaro; Loris Bernard; Giulio F Draetta; Myriam Alcalay; Christian Seiser; Susanna Chiocca
Journal:  Mol Cell Biol       Date:  2007-04-30       Impact factor: 4.272

10.  Critical review of non-histone human substrates of metal-dependent lysine deacetylases.

Authors:  Tasha B Toro; Terry J Watt
Journal:  FASEB J       Date:  2020-08-30       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.